Publikationen, an denen er mitarbeitet JOSÉ JAVIER FERNÁNDEZ RUIZ (41)

2024

  1. Involvement of CB1 and CB2 receptors in neuroprotective effects of cannabinoids in experimental TDP-43 related frontotemporal dementia using male mice

    Biomedicine and Pharmacotherapy, Vol. 174

2023

  1. Preclinical investigation in FAAH inhibition as a neuroprotective therapy for frontotemporal dementia using TDP-43 transgenic male mice

    Journal of neuroinflammation, Vol. 20, Núm. 1, pp. 108

2022

  1. New Statement about NRF2 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

    Biomolecules, Vol. 12, Núm. 9

2021

  1. Bip heterozigosity aggravates pathological deterioration in experimental amyotrophic lateral sclerosis

    International Journal of Molecular Sciences, Vol. 22, Núm. 22

  2. Chapter 2: Phytocannabinoids Versus Endocannabinoids. A Modern View of the Endocannabinoid System

    RSC Drug Discovery Series (Royal Society of Chemistry), pp. 10-47

  3. Inactivation of the CB2 receptor accelerated the neuropathological deterioration in TDP-43 transgenic mice, a model of amyotrophic lateral sclerosis

    Brain Pathology, Vol. 31, Núm. 6

  4. Preclinical investigation in neuroprotective effects of the gpr55 Ligand VCE-006.1 in experimental models of Parkinson’s disease and amyotrophic lateral sclerosis

    Molecules, Vol. 26, Núm. 24

  5. Recent advances in the pathogenesis and therapeutics of amyotrophic lateral sclerosis

    British Journal of Pharmacology

  6. Targeting the CB2 receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis

    British Journal of Pharmacology, Vol. 178, Núm. 6, pp. 1373-1387

2020

  1. Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1δ kinase inhibitor treatment

    Scientific Reports, Vol. 10, Núm. 1

  2. Pharmacokinetics of sativex® in dogs: Towards a potential cannabinoid-based therapy for canine disorders

    Biomolecules, Vol. 10, Núm. 2

2019

  1. Targeting glial cannabinoid CB2 receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis

    British Journal of Pharmacology, Vol. 176, Núm. 10, pp. 1585-1600

2018

  1. Analysis of endocannabinoid receptors and enzymes in the post-mortem motor cortex and spinal cord of amyotrophic lateral sclerosis patients

    Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, Vol. 19, Núm. 5-6, pp. 377-386

  2. Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1G93A transgenic mice, an experimental model of amyotrophic lateral sclerosis

    Biochemical Pharmacology, Vol. 157, pp. 217-226

2017

  1. Upregulation of CB2 receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis

    DMM Disease Models and Mechanisms, Vol. 10, Núm. 5, pp. 551-558

2015

  1. A Sativex®-like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis

    British Journal of Pharmacology, Vol. 172, Núm. 14, pp. 3579-3595

  2. Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders

    Journal of Neuroimmune Pharmacology, Vol. 10, Núm. 2, pp. 233-244

  3. Endocannabinoids and amyotrophic lateral sclerosis

    Cannabinoids in Neurologic and Mental Disease (Elsevier Inc.), pp. 99-123

  4. The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Δ9-tetrahydrocannabinol acting through CB1 receptors

    Multiple Sclerosis and Related Disorders, Vol. 4, Núm. 6, pp. 505-511

2014

  1. Changes in endocannabinoid receptors and enzymes in the spinal cord of sod1g93a transgenic mice and evaluation of a sativex®-like combination of phytocannabinoids: Interest for future therapies in amyotrophic lateral sclerosis

    CNS Neuroscience and Therapeutics, Vol. 20, Núm. 9, pp. 809-815